Go Pro

Liquidia (NASDAQ:LQDA) Insider Sells $3,703,000.00 in Stock

Liquidia logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Insider sale: Rajeev Saggar sold 50,000 Liquidia shares for approximately $3.70 million at an average price of $74.06, reducing his direct stake by 26.01% to 142,265 shares. He also sold shares in two earlier transactions.
  • Stock and earnings: Liquidia shares rose 1.3% to $75.33, while the company reported quarterly revenue of $171.68 million, up 1,842.1% year over year, but missed earnings expectations by $0.02 per share.
  • Investor outlook: Institutional investors own 64.54% of the company, and analyst opinions are mixed; despite a consensus “Hold” rating, the average price target is $98.08, with several firms maintaining Buy or Strong Buy ratings.
  • Five stocks to consider instead of Liquidia.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) insider Rajeev Saggar sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total value of $3,703,000.00. Following the transaction, the insider directly owned 142,265 shares in the company, valued at approximately $10,536,145.90. This represents a 26.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Rajeev Saggar also recently made the following trade(s):

  • On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The stock was sold at an average price of $76.84, for a total value of $2,269,392.56.
  • On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total value of $709,808.26.

Liquidia Trading Up 1.3%

Liquidia stock traded up $1.00 during trading on Wednesday, hitting $75.33. The company's stock had a trading volume of 1,155,908 shares, compared to its average volume of 1,795,268. The stock has a market capitalization of $6.74 billion, a price-to-earnings ratio of 54.99 and a beta of 0.58. The stock's fifty day moving average is $79.15 and its 200 day moving average is $55.70. Liquidia Corporation has a 1-year low of $21.15 and a 1-year high of $93.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analysts' expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The business's quarterly revenue was up 1842.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.49) earnings per share. As a group, equities research analysts predict that Liquidia Corporation will post 2.57 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP grew its stake in shares of Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company's stock valued at $2,179,000 after acquiring an additional 24,555 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Liquidia by 63.3% in the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company's stock valued at $2,199,000 after purchasing an additional 22,592 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new position in Liquidia in the fourth quarter valued at about $709,000. WCG Wealth Advisors LLC grew its stake in Liquidia by 98.2% during the 4th quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company's stock valued at $1,877,000 after purchasing an additional 26,957 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Liquidia by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company's stock valued at $138,439,000 after purchasing an additional 52,671 shares in the last quarter. Institutional investors and hedge funds own 64.54% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on LQDA. Jefferies Financial Group reissued a "buy" rating and issued a $60.00 target price on shares of Liquidia in a research report on Monday, May 11th. Zacks Research lowered shares of Liquidia from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 13th. BTIG Research increased their price target on shares of Liquidia from $109.00 to $111.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Raymond James Financial reiterated a "strong-buy" rating and issued a $106.00 price target on shares of Liquidia in a report on Thursday, August 13th. Finally, Needham & Company LLC boosted their price objective on shares of Liquidia from $70.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Liquidia currently has a consensus rating of "Hold" and an average price target of $98.08.

Read Our Latest Analysis on Liquidia

About Liquidia

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company's lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

Read More

Insider Buying and Selling by Quarter for Liquidia (NASDAQ:LQDA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Liquidia Right Now?

Before you consider Liquidia, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.

While Liquidia currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines